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Role of the mTOR Pathway in the Progression and Recurrence of 
Bladder Cancer: An Immunohistochemical Tissue Microarray 
Study
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1, In Ho Chang
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1Pathology, Chung-Ang University College of Medicine, Seoul, Korea
Purpose: Numerous trials have been conducted to develop new treatment regimens for 
superficial and invasive bladder cancer, because there is an urgent need to identify nov-
el agents to prevent the recurrence and progression of these cancers. We evaluated the 
prognostic and biological significance of mTOR pathway-related markers in patients 
with bladder cancer who had undergone transurethral resection of their bladder tumors 
and radical cystectomy.
Materials and Methods: We retrieved 208 bladder cancer specimens collected from pa-
tients between 1989 and 2007 and constructed a tissue microarray comprising 208 tu-
mor samples and 25 benign urothelium samples. Immunohistochemical staining was 
performed for mTOR, phosphorylated (phos) S6, and phos4E-BP1. The pattern, per-
centage, and intensity of staining for all three markers were evaluated.
Results: The median age at diagnosis of the patient cohort was 67 years (range: 29-87 
years), and the median follow-up was 72 months (range: 1-257 months). The expression 
of phos4E-BP1 was higher in the bladder cancer cohort than in the benign cohort, where-
as phosS6 expression was lower in the bladder cancer cohort than in the benign cohort. 
The expression of phosS6 was significantly higher in high-grade bladder cancer (p
＜0.01). There was a significant positive correlation between the H-scores of mTOR and 
phos4E-BP1 (coefficient of correlation, r=0.37, p＜0.01) as well as between the H-scores 
of mTOR and phosS6 (r=0.17, p＜0.05). In the multivariate analysis, strong phosS6 ex-
pression predicted shorter progression (p＜0.01; hazard ratio [HR], 2.516) and dis-
ease-specific survival (p＜0.01; HR, 2.396) but not overall survival (p=0.112), whereas 
strong phos4E-BP1 expression was a predictor of disease-specific survival (p＜0.05; 
HR, 2.105). Moreover, strong phosS6 expression predicted shorter recurrence-free (p
＜0.05) and progression-free (p＜0.05) survival in the superficial bladder cancer cohort.
Conclusions: Our results demonstrate that mTOR pathway activation, as assessed by 
phos4E-BP1 phosphorylation, is related to bladder cancer tumorigenesis and that S6 
protein phosphorylation is associated with a high level of disease recurrence and pro-
gression and poor cancer-specific survival.
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INTRODUCTION
Although about 80% of patients with non-muscle-invasive 
bladder cancer can be successfully treated through surgery 
and adjuvant intravesical therapy, two-thirds of patients 
experience tumor recurrence within 5 years, and high- 
grade T1 tumors and carcinoma in situ have the potential 
to progress and possibly metastasize [1]. Patients with inKorean J Urol 2011;52:466-473
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TABLE 1. Antibodies used for immunohistochemical staining
Antigen
Catalog
number
Species Source Pretreatment Dilution Incubation Staining
Positive 
control
mTOR
Phos4E-BP1
PhosS6
2983S
2855S
2211S
Rabbit mAb
Rabbit mAb
Rabbit mAb
Cell signaling
  technology
Cell signaling
  technology
Cell signaling
  technology
Citrate buffer pH 6.0
Microwave oven 20 min
Citrate buffer pH 6.0
Microwave oven 20 min
Citrate buffer pH 6.0
Microwave oven 20 min
1:50
  1:400
  1:100
1 hr/RT
1 hr/RT
1 hr/RT
Cytoplasmic
Cytoplasmic
Cytoplasmic
Breast
  cancer
Colon
  cancer
Breast
  cancer
RT: room temperature
vasive bladder cancer require a radical cystectomy. 
However, it is controversial whether neoadjuvant or ad-
juvant chemotherapy improves survival in patients with 
invasive bladder cancer, even though bladder transitional 
cell carcinoma is relatively chemotherapy-sensitive. Thus, 
during the past few decades, numerous trials have been 
conducted to develop new treatment regimens for both su-
perficial and invasive bladder cancer, because there is an 
urgent need to identify new agents to prevent bladder can-
cer recurrence and progression [2-5]. 
　The mammalian target of rapamycin (mTOR), a ubiq-
uitous serine-threonine kinase and a downstream compo-
nent of the phosphatidylinositol 3’-kinase (PI3K)/AKT/ 
phosphatase and the tensin homologue (PTEN)-signaling 
pathway, has been shown to play a critical role in the regu-
lation of protein synthesis, cell growth, proliferation, apop-
tosis, survival, and angiogenesis [6]. Furthermore, mTOR 
has also been demonstrated to act as a transitional activa-
tor of hypoxia-inducible factor (HIF) through its activated 
downstream molecules, namely phosphorylated S6 pro-
tein (phosS6) and phosphorylated eukaryotic translation 
initiation factor 4E-binding protein-1 (phos4E-BP1) [7]. 
Indeed, elevated mTOR pathway activity has been noted 
to be important in a variety of human tumors both in vivo 
and in vitro and in bladder cancer in vitro [8-12].
　In this study, we investigated the expression and recip-
rocal interplay of three mTOR pathway-related markers 
(mTOR, phosS6, and phos4E-BP1) to determine the prog-
nostic and biological significance of these mTOR path-
way-related markers in patients with bladder cancer who 
had undergone transurethral resectioning of their bladder 
tumor (TURB) as well as radical cystectomy.
MATERIALS AND METHODS
1. Patient cohort and tissue microarray construction
After obtaining institutional review board approval, we re-
trieved 208 bladder cancer specimens collected at Chung- 
Ang University Hospital between 1989 and 2007. We ex-
cluded samples from patients who had a history of pre-
operative treatment including radiotherapy, systemic che-
motherapy, or intravesical therapy. All sections were re-
viewed to confirm the original diagnosis and were then 
staged according to the 2004 American Joint Committee on 
Cancer (AJCC)/Union International Contre le Cancer 
TNM, 6th Edition Pathology Reporting Protocol, including 
TNM and AJCC stages. Grading was performed at the time 
of surgery by using either the World Health Organization/ 
International Society of Urological Pathology consensus 
classification or the 1965 classification [13,14]. Given the 
different grading systems used during the span of our 
study, standardization was performed by an expert uro-
logic pathologist (TJ Lee), who classified all tumors as ei-
ther high-grade or low-grade for statistical analyses. Para-
ffin blocks were available for 208 cases, and tissue micro-
arrays (TMAs) were constructed by using a manual array 
device (TMA set, Labro, Seoul, Republic of Korea). Two- 
millimeter-thick triplicate tumor samples were spotted 
from each sample, and 35 triplicate benign urothelium 
samples were obtained from the benign regions. Four-mi-
crometer-thick sections were consecutively incised from 
the recipient block and transferred to polylysine-coated 
glass slides. Hematoxylin and eosin staining was per-
formed on the TMAs to confirm the presence of tumor tissue 
or benign urothelium.
2. Clinicopathological data
All patients’ clinicopathological data were retrieved from 
electronic medical records. These included patient demo-
graphics and preoperative information such as diagnostic 
procedures and clinical stage. Follow-up data on disease re-
currence, progression, disease-specific survival (DSS), and 
overall survival (OS) were obtained by review of patient 
medical records, letters of inquiry to patients, and a review 
of the social security death index. For patients who had un-
dergone partial or radical cystectomy, pelvic recurrence as 
well as recurrent metastatic disease were considered to be 
progression events. 
3. Immunohistochemistry
For the immunohistochemical procedures, 4 μm-thick sec-
tions were deparaffinized, rehydrated, and subjected to 
heat-induced antigen retrieval with buffer solution using 
a streamer autoclave. Sections were then incubated with 
the appropriate primary antibody. After the application of 
a secondary antibody, slides were developed using the 
chromogen 3-3’-diaminobenzidine and counterstained 
with hematoxylin. Table 1 lists all pertinent marker in-Korean J Urol 2011;52:466-473
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FIG. 1. Expression of mTOR pathway-related markers in bladder tissues. (A) Immunohistochemical staining of mTOR, phosS6, and 
phos4E-BP1 in paraffin-embedded sections of benign urothelium, as well as low and high-grade bladder cancer tissues (x100). (B) 
Graph displaying comparisons of H-scores of mTOR, phosS6, and phos4E-BP1 with respect to benign and bladder cancer lesions. The
mean H-scores for phos4E-BP1 were significantly higher and the mean H-scores for phosS6 were significantly lower in bladder cancer
lesions, but the mean H-scores for mTOR were not significantly different between benign and cancerous lesions. (C) Graph displaying
the H-scores for phosS6 and phos4EBP1 in relation to mTOR H-scores in bladder cancer cells. The mean H-scores of phos4EBP1 were
significantly higher in tumor cells with strong mTOR immunostaining than in non-or weak immunostaining tumor cells, although
the mean H- score of phosS6.
formation, including vendor, clone, dilution, pretreatment 
and incubation conditions, staining site, and positive 
controls. TMA spots with artificial folds or those lacking 
target tissue representation were omitted from further 
analyses. Tumors and benign TMA spots stained with each 
marker were evaluated for patterns of staining (nuclear vs. 
cytoplasmic), extent (percent of positive cells), and in-
tensity (0 to 3＋  score). An H-score was generated for each 
marker as the sum of the products of each intensity cat-
egory multiplied by the extent of immunoexpression [15]. 
A final H-score was generated by taking the average of trip-
licate tissue samples. The H-scores of markers were used 
in the statistical analyses. In univariate and multivariate 
analyses, a cutoff value of expression of each marker was 
used according to the mean tumor H-score (H-score≥141, 
125, and 44, for mTOR, phos4E-BP1, and phosS6, re-
spectively). We defined strong expression of a marker as 
expression equal to or greater than the cutoff value, and 
weak expression as no expression or expression less than 
the cutoff value.
4. Statistical analysis
SPSS ver. 14.0 (SPSS Inc., Chicago, IL, USA) was used for 
all statistical analyses. Differences between two variables 
were investigated by using a two-tailed Student’s t-test, 
and ANOVA analysis was used when comparing more than 
three variables. Pearson correlation coefficients were cal-
culated to test relationships among parameters. Recur-Korean J Urol 2011;52:466-473
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TABLE 2. Clinicopatholgical characteristics of patients and summary of mTOR-related biomarker expression (mean H-score) with 
respect to categorized pathological parameters
Clinical and pathologic features No. of patients (%)
mTOR phos4E-BP1 phosS6
H-score 
(mean±SD) 
p-value
H-score 
(mean±SD) 
p-value
H-score 
(mean±SD) 
p-value
Age
Sex 
TNM stage 
Grade 
＜60
60-70
＞70
Male
Female
A
1
2
3
4
Low (I, II)
High (III)
  65 (31.3)
  83 (39.9)
  60 (28.8)
182 (88.8)
  26 (11.2)
  54 (26.0)
102 (49.0)
  28 (13.5)
  9 (4.3)
15 (7.2)
109 (52.4)
  99 (47.6)
145.3±91.5
150.3±79.7
119.1±75.4
142.3±85.2
132.3±71.2
140.6±84.7
149.0±81.4
  90.7±83.9
  99.8±79.3
  96.4±79.4
143.1±85.8
138.9±82.3
0.074
0.570
0.081
0.721
125.4±83.7
123.5±81.4
124.7±79.9
126.7±81.5
117.1±83.7
113.7±78.9
123.9±82.9
143.9±87.7
126.8±84.2
133.2±84.0
117.3±78.4
135.5±83.2
0.991
0.575
0.468
0.107
32.4±56.7
43.8±68.5
53.7±64.6
44.5±66.3
41.2±57.6
30.2±46.1
50.8±73.6
47.4±59.4
39.1±79.2
42.2±71.1
27.0±43.6
63.0±79.0
0.184
0.810
0.444
＜0.001
phos4E-BP1: phosphorylated 4E-BP1, phosS6: phosphorylated S6
rence-free and progression-free survival curves were esti-
mated by using the Kaplan-Meier method, and any differ-
ences in the survival curves were compared by log-rank 
tests. A Cox regression model was used during multi-
variate analysis and p＜0.05 was considered significant.
RESULTS
1. Demographic, clinical, and treatment characteristics
The median age at diagnosis for the patient cohort was 67 
years (range: 29-87 years) with a male to female ratio of 9:1 
and a median follow-up period of 72 months (range: 1-257 
months). In our cohort, 154 patients (74%) were diagnosed 
with carcinoma in situ or superficial bladder cancer and 54 
(26%) with invasive or metastatic bladder cancer. One hun-
dred sixty patients (76.9%) had undergone TURB, and 46 
(22.1%) had undergone partial or radical cystectomy. 
Recurrence was observed in 88 patients (42.3%) and pro-
gression in 53 (25.5%). Rates of OS and DSS were 54.8% 
and 78.4%, respectively. 
2. Expression of mTOR pathway-related markers in rela-
tion to clinicopathological variables
As shown in Fig. 1A, mTOR, phos4E-BP1, and phosS6 were 
expressed in the cytoplasm of bladder cancer cells and in 
benign urothelium. Overall, mTOR expression was de-
tected in 197 (94.7%) of 208 bladder cancer samples and in 
31 (88.6%) of 35 benign samples. Phos4E-BP1 and phosS6 
were expressed in 96.2% and 72.6% of bladder cancer co-
hort samples, respectively, and in 71.4% and 94.3% of be-
nign cohort samples, respectively. The mean H-score of 
phos4E-BP1 was higher in the bladder cancer cohort (125.5 
vs. 61.2) than in the benign cohort, whereas the mean 
H-score of phosS6 was lower in the bladder cancer cohort 
than in the benign cohort (44.0 vs. 183.8). The H-score of 
mTOR was not significantly different between these two 
cohorts (141.0 vs. 141.9) (Fig. 1B). In the univariate analy-
sis, there was no relationship between the H-scores of the 
markers and age, sex, or TMN stage grouping; however, the 
mean H-score of phosS6 expression was significantly high-
er in high-grade bladder cancer samples (63.0 vs. 27.0, p＜ 
0.01). Levels of the other two markers were not related to 
tumor grade (Table 2). 
　When we investigated the correlation between the ex-
pression of mTOR pathway-related markers, we found a 
significant positive correlation between mTOR and 
phos4E-BP1 H-scores (correlation coefficient, r=0.37, p
＜0.01), as well as between mTOR and phosS6 H-scores 
(r=0.17, p＜0.05), although the correlation coefficient be-
tween mTOR and phosS6 was weak. Fig. 1C shows the 
mean H-scores of phosS6 and phos4EBP1 in relation to 
mTOR H-scores in bladder cancer. The mean H-scores of 
phos4EBP1 were significantly higher in cancer cells that 
strongly expressed mTOR than in cancer cells with no or 
weak mTOR expression (p＜0.05). The mean H-scores of 
phosS6 were higher.
3. Univariate and multivariate survival analyses
Table 3 shows the results of the univariate and multi-
variate survival analyses. In the univariate analysis, a 
higher TNM stage and a higher cell grade were significant 
predictors of shorter progression, DSS, and OS. Further-
more, older age was associated with shorter progression 
and OS (p＜0.05), although older age was of borderline sig-
nificance in predicting DSS (p=0.080). Among mTOR path-
way-related markers, only phosS6 was a significant pre-
dictor of progression, DSS, and OS, although mTOR was 
a predictor of OS, and phos4E-BP1 was a predictor of DSS. 
In the multivariate analysis, TNM stage and age remained 
independent predictors of progression, DSS, and OS, but 
not of tumor cell grade. Among the markers, strong phosS6 
expression predicted shorter progression (p＜0.01; hazard Korean J Urol 2011;52:466-473
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FIG. 2. Kaplan-Meier curves based on phospS6 and phos4E-BP1 staining results in superficial bladder cancer patients. (A) In the 
recurrence-free survival curves, bladder cancers with strong pS6 immunostaining exhibited decreased recurrence-free survival 
(p=0.046, log-rank test). (B) Tumors with strong pS6 immunostaining showed significantly decreased progression-free survival 
(p=0.035, log-rank test). (C, D) Phos4E-BP1 status, however, was not related to recurrence-free survival (C) or progression-free 
survival (D) in superficial bladder cancers.
ratio [HR], 2.516) and DSS (p＜0.01; HR, 2.396), but not OS 
(p=0.112), whereas strong phos4E-BP1 expression was a 
predictor of DSS (p＜0.05; HR, 2.105). 
4. Correlation between mTOR pathway-related marker ex-
pression status and progression-free survival and re-
currence-free survival in patients with superficial blad-
der cancer
Of 154 superficial bladder cancer patients, 145 had under-
gone TURB, and in these patients, we investigated the cor-
relation between mTOR pathway-related marker ex-
pression and progression-free survival and recurrence- 
free survival. The median age of this cohort was 64 years 
(range: 29-85 years) with a male to female ratio of 8.5:1.5 
and a median follow-up of 72 months (range: 1-257 mon-
ths). In our cohort, recurrence was observed in 59 patients 
(40.7%) and progression in 35 (24.1%). Kaplan-Meier sur-
vival analysis revealed that of the three mTOR-related 
markers, only strong phosS6 expression predicted shorter 
recurrence-free (p=0.046) and progression-free survival 
(p=0.035), although the p-value was not strong (Fig. 2). 
DISCUSSION
It is well established that bladder cancer develops along 
two major molecular tracks [16]. The first track is charac-
terized by the development of papillary lesions that rarely 
become invasive or metastatic but almost always recur 
[16]. These superficial tumors are therefore rarely lethal, 
but their high recurrence rates coupled with patient lon-
gevity have made them the most expensive solid tumors to 
treat and, therefore, a significant public health burden. 
Superficial tumors are thought to be driven by Ras path-
way activation, most often (in up to 65% of cases) via the 
accumulation of activating mutations in the type 3 fibro-
blast growth factor receptor and less often via mutations 
in PI3K or Ras [17-19]. The second progression track in-
volves the inactivation of major tumor suppressors [p53, Korean J Urol 2011;52:466-473
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Rb, and PTEN], which produces tumors that are highly in-
vasive and metastatic [16,19]. Furthermore, PTEN loss 
leading to activation of the mTOR pathway has been re-
ported in other genitourinary tract tumors such as prostate 
adenocarcinoma, renal cell carcinoma, upper tract ur-
othelial carcinoma, and bladder urothelial carcinoma, of-
fering a rationale for the limited but promising response 
of these types of tumors to mTOR inhibitors [20-24].
　In our study, phos4E-BP1 expression was higher and 
phosS6 expression was lower in the bladder cancer cohort 
than in the benign cohort, although mTOR expression was 
not significantly different between these two cohorts. 
Schultz et al reported lower phosS6 expression in a bladder 
cancer cohort than in a benign urothelium cohort in a study 
of 144 bladder cancer patients who had undergone radical 
cystectomy [25]; they suggested that their findings were 
consistent with reduced activation of AKT, resulting in an 
overall down-regulation of the mTOR pathway. In our 
study, we observed a similar phosS6 expression pattern to 
that reported by Schultz and colleagues; however, in our 
study, the expression of mTOR was not increased. If these 
effects are due to down-regulation of mTOR, mTOR (nonac-
tivated form) expression should have been elevated in blad-
der urothelial carcinoma samples compared with benign 
urothelium samples. Moreover, in our study, the bladder 
cancer cohort exhibited higher expression of phos4E-BP1 
than seen in benign epithelium, indicating that the mTOR 
pathway was active. We believe that high phos4E-BP1 ex-
pression may be related to bladder cancer tumorigenesis. 
4E-BP-1 is a protein that binds to the eukaryotic trans-
lation initiation factor4E (elF-4E) and plays a critical role 
in the regulation of gene expression. When 4E-BP1 is non-
phosphorylated, it has been shown to bind tightly to elF-4E, 
blocking the formation of the cap-dependent mRNA trans-
lation initiation complex and suppressing translation. 
When 4E-BP1 is phosphorylated, elF-4E is released, and 
the initiation complex can form and promote translation 
[26]. Several studies have implicated components of the 
protein initiation synthesis apparatus in carcinogenesis. 
For example, elF-4E was shown to induce malignant trans-
formation when overexpressed in mammalian cells [27]. 
Moreover, increased levels of elF-4E are commonly found 
in breast, prostate, and head and neck tumors, but not in 
benign lesions [28].
　In our study, there was a significant positive correlation 
between mTOR and phos4E-BP1 expression as well as be-
tween mTOR and phosS6 expression in the bladder cancer 
cohort. Furthermore, phosS6 expression was elevated in 
bladder cancer cells compared with benign urothelium. 
PhosS6 expression was also significantly higher in high- 
grade bladder cancer cells. These results suggest that the 
mTOR pathway may contribute to the aggressiveness and 
progression of bladder cancer.
　Among the mTOR pathway-related markers that we 
evaluated, phosS6 was a significant predictor of pro-
gression and DSS in the multivariate survival analysis, 
and phos4E-BP1 was a significant predictor of DSS. These 
findings are similar to those for other solid tumors; how-
ever, they are in contrast with prior studies that reported 
that phosS6 had a favorable prognostic effect in bladder 
cancer [25,29]. However, in the study by Schultz et al , 42% 
of the bladder cancer cohort underwent preoperative treat-
ment including radiotherapy, systemic chemotherapy, or 
intravesical therapy [25]. Systemic chemotherapy and in-
travesical Bacillus Calmette Guerin (BCG) therapy may 
affect the expression of mTOR pathway-related markers 
as a result of telomerase activity and immune reactions 
[30,31]. In our study, therefore, we excluded patients with 
a history of preoperative treatment. Moreover, 49% of the 
bladder urothelial carcinoma cohort had a tumor staged 
higher than T3, whereas only 21% of the superficial bladder 
urothelial carcinoma cohort had a tumor at stage T3 or 
higher. A large proportion of patients with higher-stage 
bladder cancer may have a down-regulated mTOR path-
way due to activation of HIF-1α. Additional large cohort 
studies are needed to determine the prognostic sig-
nificance of mTOR pathway-related markers in bladder 
cancer patients.
　In our study, strong phosS6 expression predicted shorter 
recurrence-free and progression-free survival in 145 pa-
tients with superficial bladder cancer who had undergone 
TURB, demonstrating that the mTOR pathway is involved 
in bladder cancer recurrence and progression. Moreover, 
these findings suggest that mTOR signaling may play a 
critical role in the progression and recurrence of superficial 
bladder cancer. Seager et al reported that rapamycin, an 
mTOR inhibitor, prevented progression of carcinoma in 
situ to invasive bladder cancer in an animal model [32]; fur-
thermore, intravesical delivery of rapamycin into the blad-
der lumen was highly effective at suppressing bladder can-
cer recurrence. The risk of recurrence in patients with su-
perficial bladder cancer treated with surgical resection 
alone ranges from 45% to 80% and in intravesical BCG it 
ranges from 46% to 69% based on 5- and 10-year follow-ups, 
respectively [1]. If currently available intravesical agents 
fail to eliminate the tumor, patients are faced with the pros-
pect of radical cystectomy or urinary diversion. These are 
life-altering procedures fraught with significant metabolic 
and surgical complications, and the reluctance to accept 
these interventions hinges on the expected decrease in 
quality of life or comorbid medical conditions. Our findings 
suggest that superficial bladder cancer patients may be 
ideal candidates for testing mechanism-based targeted 
therapies in a clinical setting. 
CONCLUSIONS
Our results revealed that mTOR pathway activation, as as-
sessed by phos4E-BP1 phosphorylation, is involved in 
bladder cancer tumorigenesis and that S6 protein phos-
phorylation is a predictor of disease progression and poor 
cancer-specific survival. Moreover, we showed for the first 
time that S6 protein phosphorylation is related to high re-
currence and disease progression in superficial bladder Korean J Urol 2011;52:466-473
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cancer patients. Trials designed to evaluate novel targeted 
agents in patients who are most likely to respond will accel-
erate the development of promising therapies. We hope 
that bladder cancer will rank highly among those human 
tumors to be effectively prevented and treated by 
“individualized” therapy.
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